| Autor: |
Misyurin, V., Misyurin, A., Lukina, A., Krutov, A., Kesaeva, L., Soldatova, I., Akhlynina, T., Lyzhko, N., Burova, O., Morozova, L., Mikhaylova, I., Baryshnikova, M., Baryshnikov, A. |
| Zdroj: |
Biochemistry (Biokhimiya). Supplemental Series A, Membrane & Cell Biology; Jul2014, Vol. 8 Issue 3, p240-244, 5p |
| Abstrakt: |
A growing number of evidence indicates that cancer-testis antigens (CTA) can be used as specific targets for immune therapy of malignant melanoma. The aim of this study was to provide a basis for selecting the most suitable CTA by analyzing the mRNA expression profile of genes encoding CTA in melanoma cell lines. We used a real-time quantitative PCR to measure the expression level for the following genes: GAGE1, NY-ESO-1, MAGEA1, PASD, SCP1, SEMG1, SPANXA, SSX1, and PRAME. The objects of study were cell lines mel P, mel Si, mel Mtp, mel Il, mel Hn, mel Ibr, and mel Kor obtained from patients diagnosed with disseminated melanoma. We established that the highest frequency of occurrence and the highest expression level had the following genes: GAGE1, NY-ESO-1, MAGEA1, SCP1, SPANXA, SSX1, and PRAME. Their mRNA translation products can be promising candidates for immunotherapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink